

# Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults with Cardiovascular Risk Factors

Version 2.0; April, 2016

Prepared by  
Steven P. Dehmer, PhD<sup>1</sup>  
Michael V. Maciosek, PhD<sup>1</sup>  
Thomas J. Flottemesch, PhD<sup>2</sup>



<sup>1</sup>HealthPartners Institute  
8170 33<sup>rd</sup> Avenue South  
PO Box 1524, MS 23301A  
Minneapolis MN 55440-1524

<sup>2</sup>Contributed while employed by HealthPartners Institute; now at Truven Health Analytics, an IBM Company

The Prevention Priorities Project was funded by Centers for Disease Control and Prevention (Cooperative Agreement Numbers 5H25PS003610 and U58/CC0322077-02-01), the Robert Wood Johnson Foundation, WellPoint (now Anthem) Foundation, American Heart Association, and HealthPartners Institute. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

This report summarizes estimates of health impact and cost-effectiveness that were created to assess the relative value of most of the clinical preventive services recommended by the United States Preventive Services Task Force (USPSTF) and the Advisory Committee on Immunization Practices (ACIP). This ranking of clinical prevention priorities is guided by the National Commission on Prevention Priorities (NCPPI).

### **A. USPSTF Recommendation**

In 2014, the U.S. Preventive Services Task Force (USPSTF) updated its 2003 recommendation of behavioral counseling to promote healthful diet and physical activity for cardiovascular disease (CVD) prevention in adults with CVD risk factors.<sup>1,2</sup> The updated recommendation focuses its target population to persons who are overweight and obese and have additional CVD risk factors. The Task Force found adequate evidence that behavioral counseling has moderate benefits for this population with small to no corresponding harms (a “B” recommendation).

### **B. Choice of Population**

Based on the Task Force recommendation, we evaluate behavioral counseling to promote a healthful diet and physical activity among adults aged 18 and older with a body mass index (BMI) of 25 kg/m<sup>2</sup> or higher and any of the following known CVD risk factors: hypertension, dyslipidemia, or diabetes.

### **C. Model Type**

Analyses in this study were conducted using the HealthPartners Institute ModelHealth™: Cardiovascular disease microsimulation model. ModelHealth: CVD is an annual-cycle microsimulation model, parameterized to estimate the lifetime incidence of CVD events and associated costs in a cross-section of individuals representative of the U.S. population. Additional model details are included in the ModelHealth: CVD Technical Supplement.

Disease outcomes in ModelHealth: CVD include incidence of myocardial infarction, stroke, congestive heart failure, angina pectoris, intermittent claudication, and CVD-related death. Events are predicted by one-year risk equations estimated specifically for the model from Framingham Heart Study data.<sup>3,4</sup> Event risk is based on a person's age, sex, BMI, systolic blood pressure (SBP), high- and low-density lipoprotein (HDL and LDL) cholesterol, smoking status, and history of CVD.

The annual progression of BMI is derived from recall data reported in the Behavioral Risk Factor Surveillance System,<sup>5</sup> and the natural history of SBP and cholesterol is estimated using Framingham Heart Study data.<sup>3,4</sup> Tobacco initiation and cessation probabilities are derived from the National Health Interview Survey data<sup>6</sup> and published estimates from longitudinal studies.<sup>7,8</sup> Screening and treatment for hypertension and dyslipidemia in the model are consistent with national clinical guidelines,<sup>9,10</sup> and identification and treatment adherence patterns are consistent with the rates observed within the National Health and Nutrition Examination Survey (NHANES).<sup>11-15</sup> Use of antihypertensive drugs and lipid-acting agents is modeled as an exogenous treatment effect on SBP and cholesterol, respectively, and alters disease risk accordingly.

Disease costs in ModelHealth: CVD were estimated using data from the Medical Expenditure Panel Survey (MEPS).<sup>16</sup> First-year and ongoing costs are distinguished, and the cost of drug treatment and monitoring are accounted for separately. Pharmacy costs and clinic and lab fees associated with monitoring drug therapy are derived from nationally representative sources.<sup>17-19</sup>

## D. Analysis Design

All analyses are conducted for a 4 million person birth cohort with demographic and underlying health characteristics representative of the U.S. population of age 18. Analyses compare outcomes for a simulated population with access to behavioral counseling to promote healthful diet and physical activity to the same population, all else held equal, without access to this clinical service. We assume that the screening rate for eligibility to the behavioral counseling program is 100%; however, not all eligible persons will accept enrollment in a behavioral counseling program. Specifically, we assume that 20% of the population will never agree to enroll in a behavioral counseling program. Among the remaining 80% of the population, we assume that the acceptance rate for a behavioral counseling program is 25%. We assume that 50% of the persons who enroll in a behavioral counseling program will complete the first year of the program; we assume the remaining persons will drop out at some point during the year (uniformly distributed), with costs and benefits proportionally realized. For maintenance, we assume that 75% of the persons who completed the full year of a program during the prior year will continue enrollment in the program the following year. If a person has maintained enrollment in a program continuously for 10 years, we assume that they will stick with the program for life. We assume that persons who have previously enrolled in a program but lapsed in maintenance may re-enroll at a referral acceptance rate of 25%.

Analyses were conducted from the societal perspective, which includes patient time costs, and in accordance with the “reference case” of the Panel on Cost Effectiveness in Health and Medicine.<sup>20</sup> All costs are expressed in 2012 U.S. dollars. Primary outcomes are clinically preventable burden (CPB) and the incremental cost-effectiveness (CE) ratio. CPB is given by

$$CPB = \sum_{it} QALY_{it1} - \sum_{it} QALY_{it0}$$

where QALY represents the quality-adjusted measure for a person’s life year,  $i$  is a person identifier,  $t$  denotes time, 1 represents the case with access to the specified clinical preventive service, and 0 represents the case without access to the service. Similarly, CE is given by

$$CE = \frac{\sum_{it} \frac{QALY_{it1}}{(1+r)^t} - \sum_{it} \frac{QALY_{it0}}{(1+r)^t}}{\sum_{it} \frac{Costs_{it1}}{(1+r)^t} - \sum_{it} \frac{Costs_{it0}}{(1+r)^t}}$$

where *Costs* represents total intervention, treatment<sup>21</sup> and management, and disease costs for a person,  $r$  denotes the discount rate, which is set to 3 percent. As described in further detail below, behavioral counseling to promote a healthful diet and physical activity affects BMI, diabetes incidence, LDL, HDL, and SBP. Deterministic (one-way) sensitivity analyses of key parameters were conducted by replicating simulations with all other parameters, probabilities, and population characteristics held equal.

### Treatment effects

Lin et al.<sup>22,23</sup> conducted the systematic evidence review for the USPSTF recommendation. Effects were found for BMI, diabetes incidence, LDL, HDL, and SBP, as summarized in **Table 1**. For persons who drop out midway through an intervention, the treatment effects are proportionally applied during that year.

**Table 1: Summary of treatment effects from intensive multi-component obesity interventions**

Risk Factor	Effect	Source
BMI (kg/m <sup>2</sup> )	-1.00	21,23-47
Diabetes incidence (RR)	0.54	22,29,33,35,39,41,48
LDL (mg/dL)	-3.69	21,22,24,27,28,31,35,37,39,40,43,45,47,49-53
HDL (mg/dL)	+0.97	22,27,28,31,36,37,39-41,43,45,47,49,51,54
SBP (mm Hg)	-2.06	22,26-29,31,37-41,43-47,49-59

Notes: BMI = body mass index; RR = relative risk; LDL = low-density lipoprotein; SBP = systolic blood pressure.

#### Eligibility assessment frequency

The Task Force does not report an optimal interval for assessing eligibility for referral to behavioral counseling to promote a healthful diet and physical activity; however, for our analysis, we assumed that there is at least one eligibility assessment opportunity per year.

#### Intervention costs

Intervention costs are summarized in **Table 2**. Few studies directly report costs of behavioral counseling programs to promote a healthful diet and physical activity. We estimated standardized program costs based upon program components and resource use reported in studies of interventions from which we estimated intervention effectiveness and from studies of similar intensity that were excluded from our estimation of effect size due to differences in the population to whom they were targeted. Direct medical costs for behavioral counseling interventions were estimated from the combination of two components: (a) the cost for health professional services (including dietitian, behavioral therapist, and athletic trainer) and (b) a standard cost for printed program materials (which we estimated to average \$16 in 2012 dollars).<sup>60</sup> We determined hours of health professional time from study reports and assigned costs to health professional time based on average earnings for each profession, plus total benefits costs, based on National Occupational Employment and Wage Estimates and Employer Costs for Employee Compensation.<sup>61,62</sup> We used occupation code 29-1031 for dietitians, codes 19-3031 and 21-1011 for psychologist counselors, and 29-9091 for athletic trainers. We added a 50% indirect rate for these labor costs to approximate facility costs and intervention support staff.

Direct costs incurred by participants consist of extra costs associated with exercise and healthy diet. Costs of a gym membership (assumed to be \$45 per month) or portion of a gym membership for interventions with less intensive exercise component, were added to capture average out-of-pocket costs for physical activity. For interventions with a diet component, we approximated the cost of an improved diet from two studies. From a study by Rehm et al.,<sup>63</sup> we estimated the incremental cost of improved diet from the margin between the 2nd and 4th quintiles of energy-adjusted diet cost where the quartiles were derived from 2001-2002 National Health and Nutrition Examination Survey and national food price data. The average incremental cost for higher quality diet we derived from these estimates was \$819 per year.

Time costs incurred by participants include time spent with health professionals, additional time costs for tracking diet and preparing healthy meals and for physical activity. Patient time was valued at the average hourly earnings plus benefits of all U.S. employees (\$31 per hour).<sup>62</sup>

Our standardized costs reflect total costs for patients with complete adherence with study protocol. The model incorporates adherence explicitly. Thus, average costs per patient will be lower than our

standardized costs as those failing to adhere to the entire intervention will be allotted only a portion of the intervention costs.

**Table 2: Annual costs for a healthy diet and physical activity behavioral counseling program**

	Annual Cost	Source
<b>Direct Medical Costs</b>		
Dietician Costs (including overhead)	\$ 230	29,36,60,64-72
Behavioral Therapist Costs (including overhead)	\$ 166	29,36,60,64-72
Athletic Trainer Costs	\$ 497	29,36,60,64-72
Literature/Books/Misc	\$ 3	60
<b>Total Direct Medical Costs</b>	<b>\$ 896</b>	
<b>Direct Non-Medical Costs (Excluding Patient Time)</b>		
Athletic Club Membership	\$ 540	Assumed
Food Costs	\$ 819	63,73
Transportation Costs	\$ 297	Assumed
<b>Total Direct Non-Medical Costs</b>	<b>\$ 1,656</b>	
<b>Patient Time Costs</b>		
Behavioral and Dietary Change Classes	\$ 1,035	29,36,60,62,64-71
Exercise Sessions	\$ 3,894	29,36,60,62,64-71
<b>Total Patient Time Costs</b>	<b>\$ 4,929</b>	

Notes: All costs are expressed in 2012 U.S. dollars.

#### **E. Clinically Preventable Burden (CPB) Estimate**

Our estimate of lifetime CPB for a birth cohort of 4 million persons initially aged 18 is 751,904 QALYs. In sensitivity analysis, this estimate ranged from 241,613 to 1,282,775 QALYs.

#### **F. Cost-Effectiveness (CE) Estimate**

Our estimate of the incremental cost-effectiveness of screening for and management of obesity in adults is \$103,363 per QALY. In sensitivity analysis, this estimate ranged from \$28,270 to \$219,915 per QALY.

#### **G. Limitations**

The microsimulation model design and the results of these analyses are limited by the quality of data and evidence used to inform them. Our sensitivity analysis results indicate that CPB estimates are most sensitive to adherence to behavioral counseling programs, and CE estimates are most sensitive to assumptions regarding obesity intervention efficacy and costs. The marginal benefit of healthy lifestyle counseling is dependent on baseline risk factors and disease rates, but ModelHealth: CVD is shown to validate reasonably well with U.S. data (**Technical Supplement, Table 30**).

## References

1. LeFevre ML. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med.* 2014;161(8):587-593.
2. Behavioral counseling in primary care to promote a healthy diet: recommendations and rationale. *Am J Prev Med.* 2003;24(1):93-100.
3. Framingham Heart Study-Cohort. Biologic Specimen and Data Repository Information Coordinating Center, National Institutes of Health2010.
4. Framingham Heart Study-Offspring. Biologic Specimen and Data Repository Information Coordinating Center, National Institutes of Health2010.
5. Behavioral Risk Factor Surveillance System Survey Data (2009). Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2010. [http://www.cdc.gov/brfss/technical\\_infodata/surveydata/2009.htm](http://www.cdc.gov/brfss/technical_infodata/surveydata/2009.htm).
6. National Center for Health Statistics. National Health Interview Survey, 2007. Hyattsville, Maryland: National Center for Health Statistics, Centers for Disease Control and Prevention2008.
7. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. *Nicotine Tob Res.* 2003;5(1):13-25.
8. Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz ER. Late relapse/sustained abstinence among former smokers: a longitudinal study. *Prev Med.* 2004;39(6):1156-1163.
9. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension.* 2003;42(6):1206-1252.
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106(25):3143-3421.
11. National Health and Nutrition Examination Survey Data (2001-2002). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2004. [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes01\\_02.aspx](http://wwwn.cdc.gov/nchs/nhanes/search/nhanes01_02.aspx).
12. National Health and Nutrition Examination Survey Data (2003-2004). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2005. [http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03\\_04.htm](http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03_04.htm).
13. National Health and Nutrition Examination Survey Data (2005-2006). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2007. [http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05\\_06.htm](http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm).
14. National Health and Nutrition Examination Survey Data (2007-2008). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009. [http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/nhanes07\\_08.htm](http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/nhanes07_08.htm).
15. National Health and Nutrition Examination Survey Data (2009-2010). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes09\\_10.aspx](http://wwwn.cdc.gov/nchs/nhanes/search/nhanes09_10.aspx).
16. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. 2001-2010; <http://meps.ahrq.gov/mepsweb/>.
17. Ingenix. 2012 National Fee Analyzer OPTUMInsight; 2012.
18. Walgreens. Search Results for Aspirin. 2011; <http://www.walgreens.com/search/results.jsp?Ntt=aspirin>. Accessed 7-1-11.
19. clinicaltrials.gov. A service of the U.S. National Institute of Health. PREMIER: Lifestyle Interventions for Blood Pressure Control.

- <http://clinicaltrials.gov/ct2/show/NCT00000616?term=premier&rank=12>. Accessed January 29, 2014.
20. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. *Cost-effectiveness in health and medicine*. New York: Oxford University Press; 1996.
  21. Ma J, Yank V, Xiao L, et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. *JAMA internal medicine*. 2013;173(2):113-121.
  22. Lin JS, O'Connor E, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2014;161(8):568-578.
  23. Lin JS, O'Connor EA, Evans CV, Senger CA, Rowland MG, Groom HC. *Behavioral Counseling to Promote a Healthy Lifestyle for Cardiovascular Disease Prevention in Persons With Cardiovascular Risk Factors: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force*. Rockville (MD)2014.
  24. Burke V, Beilin LJ, Cutt HE, Mansour J, Williams A, Mori TA. A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial. *J Clin Epidemiol*. 2007;60(2):133-141.
  25. Svetkey LP, Pollak KI, Yancy WS, Jr., et al. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. *Hypertension*. 2009;54(6):1226-1233.
  26. Hyman DJ, Pavlik VN, Taylor WC, Goodrick GK, Moye L. Simultaneous vs sequential counseling for multiple behavior change. *Arch Intern Med*. 2007;167(11):1152-1158.
  27. Broekhuizen K, van Poppel MN, Koppes LL, Kindt I, Brug J, van Mechelen W. Can multiple lifestyle behaviours be improved in people with familial hypercholesterolemia? Results of a parallel randomised controlled trial. *PLoS ONE*. 2012;7(12):e50032.
  28. Roumen C, Feskens EJ, Corpeleijn E, Mensink M, Saris WH, Blaak EE. Predictors of lifestyle intervention outcome and dropout: the SLIM study. *Eur J Clin Nutr*. 2011;65(10):1141-1147.
  29. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344(18):1343-1350.
  30. Ockene IS, Tellez TL, Rosal MC, et al. Outcomes of a Latino community-based intervention for the prevention of diabetes: the Lawrence Latino Diabetes Prevention Project. *Am J Public Health*. 2012;102(2):336-342.
  31. Janus ED, Best JD, Davis-Lameloise N, et al. Scaling-up from an implementation trial to state-wide coverage: results from the preliminary Melbourne Diabetes Prevention Study. *Trials*. 2012;13:152.
  32. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. *Diabetes Res Clin Pract*. 2005;67(2):152-162.
  33. Vermunt PW, Milder IE, Wielaard F, de Vries JH, van Oers HA, Westert GP. Lifestyle counseling for type 2 diabetes risk reduction in Dutch primary care: results of the APHRODITE study after 0.5 and 1.5 years. *Diabetes Care*. 2011;34(9):1919-1925.
  34. Moy TF, Yanek LR, Raqueno JV, et al. Dietary Counseling for High Blood Cholesterol in Families at Risk of Coronary Disease. *Prev Cardiol*. 2001;4(4):158-164.
  35. Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. *Diabetes Res Clin Pract*. Vol 522001:29-43.

36. Kulzer B, Hermanns N, Gorges D, Schwarz P, Haak T. Prevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomes. *Diabetes Care*. 2009;32(7):1143-1146.
37. Fagerberg B, Wikstrand J, Berglund G, Samuelsson O, Agewall S. Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study. *Am J Hypertens*. 1998;11(1 Pt 1):14-22.
38. Rodriguez Cristobal JJ, Alonso-Villaverde Grote C, Trave Mercade P, et al. Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease. *BMC research notes*. 2012;5:126.
39. Babazono A, Kame C, Ishihara R, Yamamoto E, Hillman A. Patient-motivated prevention of lifestyle-related disease in Japan: A randomized, controlled clinical trial. *Disease Management & Health Outcomes*. 2007;15(119-126).
40. Tiessen AH, Smit AJ, Broer J, Groenier KH, van der Meer K. Randomized controlled trial on cardiovascular risk management by practice nurses supported by self-monitoring in primary care. *BMC Fam Pract*. 2012;13:90.
41. Bo S, Ciccone G, Baldi C, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. *J Gen Intern Med*. 2007;22(12):1695-1703.
42. Harris MF, Fanaian M, Jayasinghe UW, et al. A cluster randomised controlled trial of vascular risk factor management in general practice. *Med J Aust*. 2012;197(7):387-393.
43. Keyserling TC, Samuel Hodge CD, Jilcott SB, et al. Randomized trial of a clinic-based, community-supported, lifestyle intervention to improve physical activity and diet: the North Carolina enhanced WISEWOMAN project. *Prev Med*. 2008;46(6):499-510.
44. Cochrane T, Davey R, Iqbal Z, et al. NHS health checks through general practice: randomised trial of population cardiovascular risk reduction. *BMC Public Health*. 2012;12:944.
45. Nilsson PM, Lindholm LH, Schersten BF. Life style changes improve insulin resistance in hyperinsulinaemic subjects: a one-year intervention study of hypertensives and normotensives in Dalby. *J Hypertens*. 1992;10(9):1071-1078.
46. Wister A, Loewen N, Kennedy-Symonds H, McGowan B, McCoy B, Singer J. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. *CMAJ*. 2007;177(8):859-865.
47. Hardcastle S, Taylor A, Bailey M, Castle R. A randomised controlled trial on the effectiveness of a primary health care based counselling intervention on physical activity, diet and CHD risk factors. *Patient Educ Couns*. 2008;70(1):31-39.
48. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. *N Engl J Med*. Vol 339 1998:12-20.
49. Kastarinen MJ, Puska PM, Korhonen MH, et al. Non-pharmacological treatment of hypertension in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. *J Hypertens*. 2002;20(12):2505-2512.
50. Kanaya AM, Santoyo-Olsson J, Gregorich S, Grossman M, Moore T, Stewart AL. The Live Well, Be Well study: a community-based, translational lifestyle program to lower diabetes risk factors in ethnic minority and lower-socioeconomic status adults. *Am J Public Health*. 2012;102(8):1551-1558.
51. de Boer PA. Chromosome segregation and cytokinesis in bacteria. *Current opinion in cell biology*. 1993;5(2):232-237.
52. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K. Preventing weight gain: one-year results of a randomized lifestyle intervention. *Am J Prev Med*. 2009;37(4):270-277.



53. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet*. 2008;371(9629):1999-2012.
54. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393-403.
55. Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control: a randomized trial. *Ann Intern Med*. 2009;151(10):687-695.
56. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA*. Vol 2892003:2083-2093.
57. Muhlhauser I, Sawicki PT, Didjurgeit U, Jorgens V, Trampisch HJ, Berger M. Evaluation of a structured treatment and teaching programme on hypertension in general practice. *Clin Exp Hypertens*. 1993;15(1):125-142.
58. Delahanty LM, Sonnenberg LM, Hayden D, Nathan DM. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial. *J Am Diet Assoc*. Vol 1012001:1012-1023.
59. Koelewijn-van Loon MS, van der Weijden T, van Steenkiste B, et al. Involving patients in cardiovascular risk management with nurse-led clinics: a cluster randomized controlled trial. *CMAJ*. 2009;181(12):E267-274.
60. Wylie-Rosett J, Swencionis C, Ginsberg M, et al. Computerized weight loss intervention optimizes staff time: the clinical and cost results of a controlled clinical trial conducted in a managed care setting. *J Am Diet Assoc*. Vol 1012001:1155-1162; quiz 1163-1154.
61. U.S. Bureau of Labor Statistics. May 2012 National Occupational Employment and Wage Estimates. 2012; [http://www.bls.gov/oes/2012/may/oes\\_nat.htm](http://www.bls.gov/oes/2012/may/oes_nat.htm). Accessed June 3, 2015.
62. Bureau of Labor Statistics. Employer Costs for Employee Compensation - September 2012. 2012; [http://www.bls.gov/news.release/archives/ecec\\_12112012.pdf](http://www.bls.gov/news.release/archives/ecec_12112012.pdf).
63. Rehm CD, Monsivais P, Drewnowski A. The quality and monetary value of diets consumed by adults in the United States. *Am J Clin Nutr*. 2011;94(5):1333-1339.
64. Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. *Diabetes*. 2005;54(5):1566-1572.
65. Parikh P, Simon EP, Fei K, Looker H, Goytia C, Horowitz CR. Results of a pilot diabetes prevention intervention in East Harlem, New York City: Project HEED. *Am J Public Health*. 2010;100 Suppl 1:S232-239.
66. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program: a randomized trial. *JAMA*. 2003;289(14):1792-1798.
67. Jalkanen L. The effect of a weight reduction program on cardiovascular risk factors among overweight hypertensives in primary health care. *Scand J Soc Med*. 1991;19(1):66-71.
68. Jones DW, Miller ME, Wofford MR, et al. The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. *Am J Hypertens*. 1999;12(12 Pt 1-2):1175-1180.
69. Munsch S, Biedert E, Keller U. Evaluation of a lifestyle change programme for the treatment of obesity in general practice. *Swiss Med Wkly*. 2003;133(9-10):148-154.
70. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. *Arch Intern Med*. 1997;157(6):657-667.

71. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*. 1998;279(11):839-846.
72. Bureau of Labor Statistics. *Occupational Employment and Wages -- May 2012*. Bureau of Labor Statistics, U.S. Department of Labor;2013.
73. Monsivais P, Aggarwal A, Drewnowski A. Following federal guidelines to increase nutrient consumption may lead to higher food costs for consumers. *Health Aff (Millwood)*. 2011;30(8):1471-1477.